Galliford Try returns to profit & resumes dividend, Piri increases digital asset investment & Vadim Alexandre on Allergy Therapeutics
If you find this podcast useful please give it a rating and review on iTunes by clicking here
On today's Vox Markets Podcast: Galliford Try returns to profit & resumes dividend, Piri increases Digital Asset investment & Vadim Alexandre on Allergy Therapeutics
Andrew Duxbury, Finance Director of Galliford Try #GFRD discusses their half year report where they've returned to profitability and have resumed the dividend.
Galliford Try is a trading name of Galliford Try Holdings plc, a leading UK construction group listed on the London Stock Exchange. Operating as Galliford Try and Morrison Construction, the group carries out building and infrastructure projects with clients in the public, private and regulated sectors across the UK.
Nick Lee, Investment Director and David Palumbo, Non-Executive Director of Pires Investment #PIRI talks about their increase in exposure to digital assets and other investments.
Pires Investments plc (AIM: PIRI) is an investment company providing investors with access to a portfolio of next generation technology businesses with significant growth potential. The Company is building an investment portfolio of high-tech businesses across areas such as Artificial Intelligence ("AI"), Internet of Things ("IoT"), Cyber Security, Machine Learning, Augmented Reality and Virtual Reality ("AR/VR"), Big Data and digital assets which the Board believes demonstrate evidence of traction and the potential for exponential growth, due to increasing global demand for development in these sectors.
(Interview starts at 7 minutes 43 seconds)
Vadim Alexandre, Head of Healthcare at SP Angel discusses Allergy Therapeutics #AGY
(Interview starts at 16 minutes 40 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.